MOL Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹509 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
₹51 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Meghmani Organics reported a weak Q3 FY26 with standalone revenue of ₹485 cr, EBITDA of ₹51 cr, and PAT of ₹22 cr. The quarter was impacted by US tariff uncertainty causing export volume decline of approximately 14% in crop protection, while the TiO2 segment remained deeply loss-making due to elevated sulfuric acid costs and withdrawal of anti-dumping duty. Management expects recovery in the crop protection segment from February-March 2026 as trade dynamics stabilize. The pigment segment is undergoing operational improvements with renewable energy initiatives expected to reduce power costs by ₹4-4.5/unit by Q2-Q3 FY27. For TiO2, management targets improvement by Q2 FY27 once anti-dumping duty is reimposed (expected shortly) and raw material prices normalize. The company has taken plant shutdown for TiO2 to minimize losses. Key risks include sustained US tariff impact on 24-25% of agrochemical revenues, uncertain Chinese competition in TiO2 despite ADD, and the massive ₹825 cr capital already deployed in TiO2 generating single-digit returns.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects agrochemical segment margins to normalize to industry average of 15-17% as tariff-related uncertainties ease and formulation mix improves (currently 40% formulations, targeting higher).
- Operational improvements including renewable energy (3.5 MW), process automation, and reduced manpower costs expected to improve pigment EBITDA margins to 8-9% starting Q1 FY27.
- Plant restart planned by mid-year once sulfuric acid prices normalize (expected June 2026) and anti-dumping duty is reimposed. DGTR work completed; finance ministry order expected in coming months.
- Routine maintenance and debottlenecking only; no major expansion capex planned as company focuses on deleveraging (₹128 cr debt repaid YTD) and improving returns on existing assets.
Risks flagged
- 24-25% of crop protection revenues are from US market. With 50% tariff, customers are buying in small quantities only as needed, avoiding inventory buildup. Recovery depends on India-US trade deal.
- Even with ADD at $460-610/ton, Chinese competitors reduced prices below economically viable levels. Management acknowledges this dynamic persisted even when ADD was in place previously. New ADD may face same challenge.
- Individual investor An Sharma raised concern that company did not properly inform investors about the ADD withdrawal on December 5th. Management claimed it was in public domain, but investor expressed dissatisfaction with disclosure practices.
- ₹825 cr total invested (₹600 cr capex + ₹225 cr losses) in TiO2 may generate only ~₹70 cr EBITDA at optimal utilization—a sub-10% return on capital. Analyst Madhuri directly questioned wisdom of continuing the project.
Key quotes
- Whoever will have the extra 50% burden on their inventory... people are afraid that you never know that someday this person will remove the extra tariff and whether there will be reversal of the duty... so even at the customer end there is lot of uncertainty. So they buy only as and when they need the material.
- The anti-dumping was imposed in 2025 in May... following that the order was challenged by the Indian paint association in Kolkata high court... it was not represented properly and the court order came in their favor... DGTR accepted the order and worked on the lapses and now we are awaiting the new order.
- ₹825 cr we have already put here. Now this plant will even in the best case scenario make a ₹70 cr EBITDA. So what kind of return on capital can be expected? I mean the downside every quarter we see the downside—it is like ₹30 cr quarterly loss and upside anyway is a single digit return on capital, sir. What's the wisdom of just carrying on with this dud project?
Research modules